Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors : vimarsana.com

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Boston , Massachusetts , United States , Texas , Filip Janku , Markus Warmuth , Jordi Rodon Ahnert , Monta Rosa Qu , Monte Rosa , Investorsandrew Funderburk , Mediacory Tromblee , Exchange Commission On , University Of Texas Md Anderson Cancer Center , Monte Rosa Therapeutics Inc , Rosa Therapeutics , Chief Executive Officer , Chief Medical Officer , Rodon Ahnert , Associate Professor , Cancer Center , Principal Investigator , Callmonte Rosa Therapeutics , Study Identifier , Engineered Elimination , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Andrew Funderburk , Cory Tromblee , Monte Rosa Therapeutics ,